IL-15-based fusions to IL-12 and IL-18

Patent metadata

Field	Value
Publication number	US-11872272-B2
Application number	US-202318168428-A
Country	US
Kind code	B2
Filing date	Feb 13, 2023
Priority date	Mar 6, 2017
Publication date	Jan 16, 2024
Grant date	Jan 16, 2024

Abstract

The invention features multi-specific fusion protein complexes with one domain comprising IL-15 or a functional variant and a binding domain specific to IL-12 or IL-18.

First claim

What is claimed is:

1. A method of activating Natural Killer (NK) cells, the method comprising exposing NK coils to an isolated soluble fusion protein complex comprising a first soluble protein comprising an interleukin-15 (IL-15) polypeptide domain and an IL-18 polypeptide domain, and a second soluble protein comprising a soluble IL-15 receptor alpha sushi (IL-15RαSu) polypeptide domain and an IL-12 polypeptide domain, wherein the IL-15 polypeptide domain binds to the IL-15RαSu polypeptide domain to form the soluble fusion protein complex, wherein the NK cells are activated.

2. The method of claim 1 , wherein the activated NK cells have increased expression of one or more activation markers, wherein the activation markers comprise CD25 and/or CD69.

3. The method of claim 1 , wherein the activated NK cells have increased cytotoxicity against cancerous or virally infected cells.

4. The method of claim 3 , wherein the activated NK cells have increased production of Interferon gamma (IFNγ).

5. The method of claim 1 , wherein the NK cells are primary NK cells.

6. The method of claim 5 , wherein the activated NK cells are comprised of Cytokine Induced Memory Like (CIML) NK cells.

7. The method of claim 1 , wherein the NK cells comprise an NK cell line.

Assignees

• Altor Bioscience Llc

Inventors

• Marcus Warren D
• Newman Robert
• Liu Bai
• You Lijing
• Kong Lin
• Rhode Peter
• Wong Hing C

Classifications

• A61K38/00

  Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title

• C12N15/63

  Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression · CPC title

• C07K14/7155

  for interleukins [IL] · CPC title

• C07K14/54

  Interleukins [IL] · CPC title

• C07K14/5443 Primary

  IL-15 · CPC title